Damora Therapeutics, Inc. (DMRA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+776.2%

$189.26

vs $21.60 price

Levered DCF

$188.96

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

26.87

Safe zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.15×	-0.25×	-0.5×	-0.47×	-1.48×	-9.07×	-9.07×	-20.07×
P/B	0.13×	0.37×	0.59×	0.47×	0.65×	1.91×	7.87×	12.44×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	1.08×	0.35×	0.06×	0.05×	-0.29×	-4.58×	-9.54×	-27.16×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	12.98×	14.07×	6.31×	5.75×	24.23×	30.42×	7.07×	7.87×
Debt / equity	0×	0.1×	0.01×	0.01×	0.01×	0.01×	0.01×	0×
Interest coverage	0×	0×	0×	0×	0×	0×	0×	-4.35×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-87.3%	-148.2%	-118.6%	-99.8%	-44.1%	-21.1%	-75.3%	-51.8%
Return on invested capital	-87.7%	-106.0%	-111.9%	-97.8%	-44.2%	-20.2%	-79.9%	-42.1%
Return on assets	-80.5%	-125.1%	-100.3%	-84.2%	-42.3%	-20.3%	-64.5%	-45.2%
Free cash flow yield	-21.4%	-346.1%	-192.9%	-147.6%	-68.6%	-12.1%	-5.1%	-3.6%
Earnings yield	-669.1%	-398.4%	-200.4%	-210.9%	-67.6%	-11.0%	-9.6%	-4.2%
Enterprise value	-$226.2M	-$7.4M	-$2.1M	-$2.8M	$14.8M	$153.4M	$370.5M	$350.5M
Net debt / EBITDA	1.23×	0.6×	0.57×	0.52×	1.2×	4.86×	0.28×	2.4×
Cash conversion cycle (days)	0	-760	-748	-2,495	-1,267	-5,535	-10,947	0